If sold after 1 year from purchase date, long term capital gain tax will be applicable. Current tax rate is 12.5%, if your total long term capital gain exceeds 1.25 lakh. Any cess/surcharge is not ...

The approval was based on data from the randomized, double-blind, placebo-controlled phase 3 SELECT-GCA trial.

30 Under 30 Europe Entertainment 2025: Ella Purnell, Alan Walker, Lola Young And The Rising Stars On Screen And On Stage 30 Under 30 Europe Manufacturing & Industry 2025: Europe’s Top Industrial ...

The FDA has approved upadacitinib, a Janus kinase inhibitor, for the treatment of giant cell arteritis in adults-marking the ...

Rinvoq (upadacitinib) becomes the first oral JAK inhibitor approved by the FDA for the treatment of giant cell arteritis in ...

AbbVie has received approval from the U.S. Food and Drug Administration (FDA) for RINVOQ (upadacitinib), 15 mg, once daily, for the treatment of adults with giant ...

AbbVie announced the US Food and Drug Administration (FDA) has approved Rinvoq (upadacitinib), 15 mg, once daily, for the treatment of adults with giant cell arteritis (GCA). This comes after the ...

AbbVie’s Rinvoq (upadacitinib) has been approved by the US Food and Drug Administration (FDA) to treat adults with giant cell arteritis (GCA), or temporal arteritis, an autoimmune disease of medium ...

NORTH CHICAGO, Ill. - AbbVie (NYSE:ABBV), a prominent player in the biotechnology industry with a market capitalization of $340 billion, announced today that the U.S. Food and Drug Administration (FDA ...

46.4% of patients receiving Rinvoq 15 mg in combination with a 26-week steroid taper regimen achieved sustained remission from week 12 to week 52, compared to 29.0% of patients receiving placebo ...

Plus, news about the No­vo Nordisk Foun­da­tion and Tonix: Ab­b­Vie’s Rin­voq gets la­bel ex­pan­sion: The block­buster JAK in­hibitor won ap­proval in … ...

AbbVie recently secured FDA approval for RINVOQ to treat giant cell arteritis, which alongside a biologics license application for TrenibotE, underscored the company's focus on innovation.